A new trading day began on Monday, with Xenon Pharmaceuticals Inc (NASDAQ: XENE) stock price up 6.50% from the previous day of trading, before settling in for the closing price of $31.40. XENE’s price has ranged from $26.74 to $46.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 35.90%. Meanwhile, its annual earnings per share averaged -34.72%. With a float of $74.20 million, this company’s outstanding shares have now reached $76.42 million.
The extent of productivity of a business whose workforce counts for 327 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Xenon Pharmaceuticals Inc (XENE) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Xenon Pharmaceuticals Inc is 3.05%, while institutional ownership is 97.31%. The most recent insider transaction that took place on Jan 24 ’25, was worth 903,214. In this transaction PRESIDENT & CEO of this company sold 22,468 shares at a rate of $40.20, taking the stock ownership to the 31,302 shares. Before that another transaction happened on Jan 27 ’25, when Company’s PRESIDENT & CEO sold 16,315 for $40.50, making the entire transaction worth $660,806. This insider now owns 31,302 shares in total.
Xenon Pharmaceuticals Inc (XENE) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -34.72% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -9.49% during the next five years compared to -14.28% drop over the previous five years of trading.
Xenon Pharmaceuticals Inc (NASDAQ: XENE) Trading Performance Indicators
Here are Xenon Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 17.85.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.01, a number that is poised to hit -0.91 in the next quarter and is forecasted to reach -4.51 in one year’s time.
Technical Analysis of Xenon Pharmaceuticals Inc (XENE)
The latest stats from [Xenon Pharmaceuticals Inc, XENE] show that its last 5-days average volume of 1.27 million was superior to 0.56 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 73.36%. Additionally, its Average True Range was 2.18.
During the past 100 days, Xenon Pharmaceuticals Inc’s (XENE) raw stochastic average was set at 39.99%, which indicates a significant decrease from 76.97% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 82.71% in the past 14 days, which was higher than the 45.12% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $35.83, while its 200-day Moving Average is $39.45. Now, the first resistance to watch is $34.37. This is followed by the second major resistance level at $35.31. The third major resistance level sits at $36.90. If the price goes on to break the first support level at $31.85, it is likely to go to the next support level at $30.26. Assuming the price breaks the second support level, the third support level stands at $29.33.
Xenon Pharmaceuticals Inc (NASDAQ: XENE) Key Stats
With a market capitalization of 2.56 billion, the company has a total of 76,543K Shares Outstanding. Currently, annual sales are 0 K while annual income is -234,330 K. The company’s previous quarter sales were 0 K while its latest quarter income was -65,690 K.
